Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHM-495
- Development stage
- Preclinical
- Lead developer
- Chemia
- Modality
- Small Molecules
01
Overview
CHM-495 is an early-stage small molecule drug candidate currently in development by Chemia, a biotechnology company specializing in generative AI for molecular design. The compound was identified and optimized using Chemia's proprietary AI platform, which integrates high-throughput experimental data with machine learning to navigate chemical space and design novel ligands for challenging biological targets. While specific details regarding its molecular target and primary clinical indication have not been publicly disclosed, CHM-495 is part of a pipeline focused on therapeutic areas such as oncology and inflammatory diseases. The program is currently in the discovery or optimization phase of development.
Beyond the preview
Go deeper on CHM-495.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHM-495.